Brainsway (BWAY) Cash from Financing Activities (2019 - 2026)
Brainsway (BWAY) posted quarterly Cash from Financing Activities of -$901000.0 for Q1 2026, down 19.34% year-on-year from -$1.1 million in Q1 2025, and up 8.71% on a QoQ basis from -$987000.0 in Q4 2025.
Brainsway (BWAY) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Brainsway (BWAY) has reported Cash from Financing Activities for 8 consecutive years, with -$901000.0 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Financing Activities fell 19.34% year-over-year to -$901000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.4 million (down 113.04% YoY) and the FY2025 annual result came in at -$1.7 million, down 109.36% from the prior year.
- Cash from Financing Activities climbed to -$901000.0 in Q1 2026 per BWAY's latest filing, from -$987000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for BWAY reached as high as $19.6 million in Q4 2024 and fell as low as -$987000.0 in Q4 2025.
- A 5-year average of $739705.9 and a median of -$377000.0 in 2023 frame the typical range for Cash from Financing Activities.
- The largest YoY upside for Cash from Financing Activities was 3816.32% in 2024 against a maximum downside of 1146.43% in 2024.
- Year by year, Cash from Financing Activities stood at -$73000.0 in 2022, then slumped by 621.92% to -$527000.0 in 2023, then jumped by 3816.32% to $19.6 million in 2024, then plunged by 105.04% to -$987000.0 in 2025, then climbed by 8.71% to -$901000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$901000.0, -$987000.0, and -$208000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Brainsway | 646.63 Mn | 587.74 Mn | 11.68 Mn | -901,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -901,000.00 |
| Mar 31, 2026 | -901,000.00 |
| Dec 31, 2025 | -987,000.00 |
| Dec 31, 2025 | -987,000.00 |
| Sep 30, 2025 | -208,000.00 |
| Sep 30, 2025 | -208,000.00 |
| Jun 30, 2025 | -264,000.00 |
| Jun 30, 2025 | -264,000.00 |
| Mar 31, 2025 | -755,000.00 |
| Mar 31, 2025 | -755,000.00 |
| Dec 31, 2024 | 19.59 Mn |
| Dec 31, 2024 | 19.59 Mn |
| Sep 30, 2024 | -698,000.00 |
| Sep 30, 2024 | -698,000.00 |
| Jun 30, 2024 | -35,000.00 |
| Jun 30, 2024 | -35,000.00 |
| Mar 31, 2024 | -589,000.00 |
| Mar 31, 2024 | -589,000.00 |
| Dec 31, 2023 | -527,000.00 |
| Dec 31, 2023 | -527,000.00 |